<DOC>
	<DOCNO>NCT02322801</DOCNO>
	<brief_summary>This multi-center , observational , retrospective-prospective cohort study investigate safety rituximab ( MabThera ) collect data daily clinical practice use rituximab relative clinical impact , particularly regard adverse event . Data patient collect 24 month enrolment study . Target sample size 325 patient .</brief_summary>
	<brief_title>Observational Safety Study Rituximab Patients Diagnosed With Rheumatoid Arthritis ( RA ) Who Did Not Respond Adequately TNF-alpha Blocker</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patients diagnose RA respond adequately antiTNFalpha start rituximab ( RTX ) treatment 12 month site initiation still treatment enrollment start Patients serious infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>